Composite Outcomes in Randomized Trials: Greater Precision but with Greater Uncertainty?

JAMA

Volumn 289, Issue 19, 2003, Pages 2554-2559

  Freemantle, Nick ^a   Calvert, Melanie ^a   Wood, John ^a   Eastaugh, Joanne ^a   Griffin, Carl ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; MEASUREMENT; MEDICAL RESEARCH; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; REVIEW; STATISTICAL ANALYSIS; TREATMENT OUTCOME; TREATMENT PLANNING; VALIDATION PROCESS; ARTICLE; METHODOLOGY; MORBIDITY; STANDARD; STATISTICS; SURVIVAL;

DATA INTERPRETATION, STATISTICAL; MORBIDITY; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0037872688     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.289.19.2554     Document Type: Review

References (18)

1. Eccles M, Freemantle N, Mason JM. Methods of developing guidelines for efficient drug use in primary care: North of England Evidence Based Guidelines Development Project. BMJ. 1998;316:1232-1235.
2. Freemantle N. Interpreting the results of secondary endpoints and subgroup analyses in clinical trials: should we lock the crazy aunt in the attic? BMJ. 2001;322:989-991.
3. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonized tripartite guideline: statistical principles for clinical trials. Stat Med. 1999;18:1905-1942.
4. Shih JH. Sample size calculation for complex clinical trials with survival endpoints. Control Clin Trials. 1995;16:395-407.
5. Le May MR, Labinaz M, Davies RF, et al. Stenting versus thrombolysis in acute myocardial infarction trial (STAT). J Am Coll Cardiol. 2001;37:985-991.
6. Leon MB, Teirstein PS, Moses JW, et al. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med. 2001;344:250-256.
7. The CAPRICORN Investigators. Effects of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385-1390.
8. Hampton JR. Clinical trial safety committees: the devil's spoon. BMJ. 2000;320:244-245.
9. Aggrastat Injection, Aggrastat Injection Premixed [package insert]. West Point, Pa: Merck; 1998.
10. Bhatt DL, Topol EJ. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA. 2000;284:1549-1558.
11. Martin DO, Austin H. An exact method for meta-analysis of case-control and follow-up studies. Epidemiology. 2000;11:255-260.
12. Lincoff AM, Califf RM, Moliterno DJ, et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. N Engl J Med. 1999;341:319-327.
13. Rodriguez A, Bernardi V, Navia J, et al. Argentine randomized study: coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple-vessel disease (ERACI II): 30-day and one-year follow-up results. J Am Coll Cardiol. 2001;37:51-58.
14. Topol EJ, Molitemo DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001;344:1888-1894.
15. SAS [computer program]. Version 8.1. Cary, NC: SAS Institute Inc; 2002 update.
16. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med. 2000;342:145-153.
17. Lindor KD, for the Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. Ursodiol for primary sclerosing cholangitis. N Engl J Med. 1997;336:691-695.
18. Moher D, Schulz KF, Altman D, for the CONSORT Group. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA. 2001;285:1987-1991.